Skip to main content
SpringerLink
Log in
Book cover

Developing Drug Products in an Aging Society pp 563–576Cite as

Vaccination in Older Adults

  • Chapter
  • First Online:

  • 1369 Accesses

Part of the book series: AAPS Advances in the Pharmaceutical Sciences Series ((AAPS,volume 26))

Abstract

Older people have an considerably increased risk for viral and bacterial infections. If these infections occur in elderly persons, the risk of severe complications and death is increased too. Ageing of the immune system and therefore risk of infections becomes significant as early as at an age of about 50+. Many infectious diseases endangering older, i.e. >50 years old humans are preventable by vaccinations . The most frequent vaccine-preventable diseases for older adults include seasonal influenza, pneumococcal diseases and herpes zoster. Every adult aged >50 years should therefore be vaccinated against these diseases. Standard vaccinations for younger adults like tetanus and hepatitis A are also mandatory for older adults as are special vaccinations for older persons living in or traveling to endemic areas. The effectiveness of many vaccines decreases with age. This implies that basic vaccinations for older adults should be started and completed as early as possible. Measures to increase vaccine effectiveness in persons with an “aged immune system” include the use of vaccines with adjuvants (e.g. MF 95 for seasonal influenza ), high dose vaccines (efficiancy documented for trivalent influence vaccine), intradermal application, and shorter booster intervals (e.g. for tick-borne encephalitis).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179–86.

    Article  PubMed  Google Scholar 

  2. Foppa IM, Cheng PY, Reynolds SB, Shay DK, Carias C, Bresee JS, Kim IK, Gambhir M, Fry AM. Deaths averted by influenza vaccination in the U.S. during the seasons2005/06 through 2013/14. Vaccine. 2015. pii: S0264–410X(15)00231-5.

    Google Scholar 

  3. Castilla J, Cia F, Zubicoa J, Reina G, Martínez-Artola V, Ezpeleta C. Influenza outbreaks in nursing homes with high vaccination coverage in Navarre, Spain, 2011/12. Euro Surveill. 2012;17(14).

    Google Scholar 

  4. Gaillat J, Dennetière G, Raffin-Bru E, Valette M, Blanc MC. Summer influenza outbreak in a home for the elderly: application of preventive measures. J Hosp Infect. 2008;70(3):272–7.

    Article  CAS  PubMed  Google Scholar 

  5. Jhung MA, D’Mello T, Pérez A, Aragon D, Bennett NM, Cooper T, Farley MM, Fowler B, Grube SM, Hancock EB, Lynfield R, Morin C, Reingold A, Ryan P, Schaffner W, Sharangpani R, Tengelsen L, Thomas A, Thurston D, Yousey-Hindes K, Zansky S, Finelli L, Chaves SS. Hospital-onset influenza hospitalizations—United States, 2010-2011. Am J Infect Control. 2014;42(1):7–11.

    Article  PubMed  Google Scholar 

  6. Sayers G, Igoe D, Carr M, Cosgrave M, Duffy M, Crowley B, O’Herlihy B. High morbidity and mortality associated with an outbreak of influenza A (H3N2) in a psycho-geriatric facility. Epidemiol Infect. 2013;141(2):357–65.

    Article  CAS  PubMed  Google Scholar 

  7. Fernandes EG, de Souza PB, de Oliveira ME, Lima GD, Pellini AC, Ribeiro MC, Sato HK, Ribeiro AF, Yu AL. Influenza B outbreak on a cruise ship off the SãoPaulo Coast, Brazil. J Travel Med. 2014;21(5):298–303.

    Google Scholar 

  8. Beyer WE, McElhaney J, Smith DJ, Monto AS, Nguyen-Van-Tam JS, Osterhaus AD. Cochrane re-arranged: support for policies to vaccinate elderly people against influenza. Vaccine. 2013;31(50):6030–9.

    Article  PubMed  Google Scholar 

  9. Lee WJ, Chen LK, Tang GJ, Lan TY. The impact of influenza vaccination on hospitalizations and mortality among frail older people. J Am Med Dir Assoc. 2014;15(4):256–60.

    Google Scholar 

  10. Udell JA, Zawi R, Bhatt DL, Keshtkar-Jahromi M, Gaughran F, Phrommintikul A, Ciszewski A, Vakili H, Hoffman EB, Farkouh ME, Cannon CP. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 2013;310(16):1711–20.

    Article  CAS  PubMed  Google Scholar 

  11. Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology. 2003;49(3):177–84.

    Google Scholar 

  12. Richardson DM, Medvedeva EL, Roberts CB, Linkin DR. Centers for disease control and prevention epicenter program. Comparative effectiveness of high-dose versus standard-dose influenza vaccination in community-dwelling veterans. Clin Infect Dis. 2015. pii: civ261.

    Google Scholar 

  13. Lemaitre M, Meret T, Rothan-Tondeur M, Belmin J, Lejonc JL, Luquel L, Piette F, Salom M, Verny M, Vetel JM, Veyssier P, Carrat F. Effect of influenza vaccination of nursing home staff on mortality of residents: a cluster-randomized trial. J Am Geriatr Soc. 2009;57(9):1580–6.

    Article  PubMed  Google Scholar 

  14. Pearson ML, Bridges CB, Harper SA. Healthcare Infection Control Practices Advisory Committee (HICPAC); Advisory Committee on Immunization Practices (ACIP). Influenza vaccination of health-care personnel: recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55(RR-2):1–16.

    Google Scholar 

  15. Arnou R, Icardi G, De Decker M, Ambrozaitis A, Kazek MP, Weber F, Van Damme P. Intradermal vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 2009;27(52):7304–12.

    Google Scholar 

  16. Van Damme T, Arnou R, Kafeja F, Fiquet A, Richard P, Thomas S, Meghlaoui G, Samson SI, Ledesma E. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomized comparative study. BMC Infect Dis. 2010;10(1):1.

    Google Scholar 

  17. Feldman C, Anderson R. Review: current and new generation pneumococcal vaccines. J Infect. 2014;69(4):309–25.

    Google Scholar 

  18. Jackson LA. Pneumococcal polysaccharide vaccines. In: Plotkin SA, Orenstein W, Offit PA, editors. Vaccines. 6th ed. 2013; p. 542–72.

    Google Scholar 

  19. Dagan R et al. Textbook of pediatric infectious diseases. Vol 1. 5th ed. Philadelphia, PA: Saunders; 2004.

    Google Scholar 

  20. Peter G, Klein JO. Principles and practice of pediatric infectious diseases. 3rd ed. New York, NY: Churchill Livingstone; 2008. p. 725–33.

    Book  Google Scholar 

  21. Watson DA, et al. Eur J Clin Microbiol Infect Dis. 1995;14:479–90.

    Article  CAS  PubMed  Google Scholar 

  22. Weinberger DM, et al. PLoS Pathog. 2009;5(6):e10000476.

    Article  Google Scholar 

  23. Alberti S, Kaye KS. The changing microbiologic epidemiology of community-acquired pneumonia. Postgrad Med. 2013;125:31–42.

    Article  Google Scholar 

  24. Baldo V, et al. A population-based study on the impact of hospitalization for pneumonia in different age groups. BMC Infect Dis. 2014;14:485.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Steens A, Vestrheim DF, de Blasio BF. Pneumococcal vaccination in older adults in the era of childhood vaccination: public health insights from a Norwegian statistical prediction study. Epidemics. 2015;11:24–31.

    Article  PubMed  Google Scholar 

  26. van der Linden M, Perniciaro S, Imöhl M. Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era. BMC Infect Dis. 2015;15(1):207.

    Google Scholar 

  27. Oishi K, Tamura K, Akeda Y. Global control of pneumococcal infections by pneumococcal vaccines. Trop Med Health. 2014;42(2 Suppl):83–6.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Davis SM, Deloria-Knoll M, Kassa HT, O’Brien KL. Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects. Vaccine. 2013;32(1):133–45.

    Google Scholar 

  29. Vila-Corcoles A, Ochoa-Gondar O. Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice. Drugs Aging. 2013;30(5):263–76.

    Article  CAS  PubMed  Google Scholar 

  30. Smit P, Oberholzer D, Hayden-Smith S, Koornhof HJ, Hilleman MR. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA. 1977;238(24):2613–6.

    Google Scholar 

  31. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;1:CD000422.

    Google Scholar 

  32. Gutierrez Rodriguez MA, Ordobas Gavin MA, Garcia-Comas L, Sanz Moreno JC, Cordoba Deorador E, Lasheras Carbajo MD, Taveira Jimenez JA, Martin Martinez F, Iniesta Fornies D, Arce Arnaez A. Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and over in the Region of Madrid, Spain, 2008–2011. Euro Surveill. 2014;19(40):20922.

    Google Scholar 

  33. Song JY, Cheong HJ, Tsai TF, Chang HA, Choi MJ, Jeon JH, Kang SH, Jeong EJ, Noh JY, Kim WJ. Immunogenicity and safety of concomitant MF59-adjuvantedinfluenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults. Vaccine. 2015.

    Google Scholar 

  34. Caya CA, Boikos C, Desai S, Quach C. Dosing regimen of the 23-valent pneumococcal vaccination: a systematic review. Vaccine. 2015;33 (11):1302–12.

    Google Scholar 

  35. Cordonnier C, Ljungman P, Juergens C, Maertens J, Selleslag D, Sundaraiyer V, Giardina PC, Clarke K, Gruber WC, Scott DA, Schmoele-Thoma B. 3003 study group. Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipientsof allogeneic hematopoietic stem cell transplant aged ≥2 years: an open-label study. Clin Infect Dis. 2015.

    Google Scholar 

  36. Tromp KM, Campbell MW, Vazquez A. Recent developments and future directions of pneumococcal vaccine recommendations. Clin Ther. 2015.

    Google Scholar 

  37. Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine. 2013;31(35):3594–602.

    Article  CAS  PubMed  Google Scholar 

  38. Pletz MW, Ewig S, Höffgen G. Stellungnahme von Experten der PEG. Chemotherapie J. 2012;21(6):109–12.

    Google Scholar 

  39. Bowsher D. Eur J Pain. 1999;3(4):335–42.

    Article  CAS  PubMed  Google Scholar 

  40. Burke BL, et al. Arch Intern Med. 1982;142:291–3.

    Article  CAS  PubMed  Google Scholar 

  41. Centers for Disease Control and Prevention. MMWR June, 2008;57:1.

    Google Scholar 

  42. Miller E et al. Rev Med Microbiol. 1993.

    Google Scholar 

  43. Wutzler P, et al. Vaccine. 2001;20:121–4.

    Article  CAS  PubMed  Google Scholar 

  44. Shaikh S. Am Fam Physician. 2002;66(9):1723–30.

    PubMed  Google Scholar 

  45. Oxman MN. Clinical manifestations of herpes zoster. In: Arvin AM, Gershon AA, editors. Varicella-Zoster virus, virology and clinical management. Cambridge: Cambridge Press; 2000. p. 246–75.

    Google Scholar 

  46. Hope-Simpson RE, Proc R. Soc Med. 1965;58:9–20.

    CAS  Google Scholar 

  47. Levin MJ, et al. J Infect Dis. 2008;197(Suppl 2):825–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Oxman MN, et al. N Engl J Med. 2005;352(22):2271–84.

    Article  CAS  PubMed  Google Scholar 

  49. Tseng HF, et al. JAMA. 2011;305:160–6.

    Article  CAS  PubMed  Google Scholar 

  50. Public health England: Herpes zoster (shingles) vaccination programme to protect the elderly. HPR7 (35) news, 30 Aug 2013

    Google Scholar 

  51. Tseng HF, et al. J Int Med. 2012;271:510–20.

    Article  CAS  Google Scholar 

  52. Baxter R, et al. Vaccine. 2012;30:6636–41.

    Article  CAS  PubMed  Google Scholar 

  53. Schmader K, et al. Clin Infect Dis. 2012;54(7):922–8.

    Article  PubMed  PubMed Central  Google Scholar 

  54. http://www.cdc.gov/vaccines/vpd-vac/shingles/hcp-vaccination.htm.

  55. http://www.phac-aspc.gc.ca/publicat/cig-gci/p04-herp-zona-eng.php#ru

  56. http://www.health.gov.au/internet/immunise/publishing.nsf/Content/handbook10-4-24

  57. Cohen JI. NEJM. 2013;369(18):1766–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barberà J, Vesikari T, Watanabe D, Weckx L, Zahaf T, Heineman TC. ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96.

    Article  PubMed  Google Scholar 

  59. Berkowitz EM, Moyle G, Stellbrink HJ, Schürmann D, Kegg S, Stoll M, El Idrissi M, Oostvogels L, Heineman TC. Zoster-015 HZ/su Study Group. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2015;211(8):1279–87.

    PubMed  Google Scholar 

  60. Sitarska-Gołebiowska J, Zieliński A. Tetanus in 2001. Przegl Epidemiol. 2003;57(1):135–7.

    PubMed  Google Scholar 

  61. Filia A, Bella A, von Hunolstein C, Pinto A, Alfarone G, Declich S, Rota MC. Tetanus in Italy 2001–2010: a continuing threat in older adults. Vaccine. 2014;32(6):639–44.

    Article  PubMed  Google Scholar 

  62. Jelenik Z, Keller M, Briggs B, Günther G, Haglund M, Hudeckova H, Jilkova E, Mickiene A, Sandell B, Steffen R, Strle F. Tick-borne encephalitis and goldenagers: position paper of the International Scientific Working Group on Tick-borneencephalitis (ISW-TBE). Wien Med Wochenschr. 2010;160(9–10):247–51.

    Article  PubMed  Google Scholar 

  63. Ly KN, Klevens RM. Trends in disease and complications of hepatitis A virus infection in the United States, 1999–2011: a new concern for adults. J Infect Dis. 2015.

    Google Scholar 

  64. Genton B, D’Acremont V, Furrer HJ, Hatz C, Louis L. Hepatitis A vaccines and the elderly. Travel Med Infect Dis. 2006;4:303–31.

    Article  PubMed  Google Scholar 

  65. Martin M, Weld LH, Tsai TF, et al. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis. 2001;7:945–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Khromava AY, Eidex RB, Weld LH, Kohl KS, Bradshaw RD, Chen RT. Cetron MS; Yellow Fever Vaccine Safety Working Group. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine. 2005;23(25):3256–63.

    Article  PubMed  Google Scholar 

  67. Monath TP. Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines. 2012;11(4):427–48.

    Article  CAS  PubMed  Google Scholar 

  68. Rafferty E, Duclos P, Yactayo S, Schuster M. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review. Vaccine. 2013;31(49):5798–805.

    Article  PubMed  Google Scholar 

  69. Whittembury A, Ramirez G, Hernández H, Ropero AM, Waterman S, Ticona M, Brinton M, Uchuya J, Gershman M, Toledo W, Staples E, Campos C, Martínez M, Chang GJ, Cabezas C, Lanciotti R, Zaki S, Montgomery JM, Monath T, Hayes E. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine. 2009;27(43):5974–81.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department for Geriatrics, Alexian Krefeld GmbH, Krefeld, Germany

    Andreas H. Leischker

Authors
  1. Andreas H. Leischker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andreas H. Leischker .

Editor information

Editors and Affiliations

  1. Graz University of Technology, Graz, Austria

    Sven Stegemann

Rights and permissions

Reprints and permissions

Copyright information

© 2016 American Association of Pharmaceutical Scientists

About this chapter

Cite this chapter

Leischker, A.H. (2016). Vaccination in Older Adults. In: Stegemann, S. (eds) Developing Drug Products in an Aging Society. AAPS Advances in the Pharmaceutical Sciences Series, vol 26. Springer, Cham. https://doi.org/10.1007/978-3-319-43099-7_26

Download citation

Publish with us

Policies and ethics

Search

Navigation